Generalisable long COVID subtypes: Findings from the NIH N3C and RECOVER programmesResearch in context

Autor: Justin T. Reese, Hannah Blau, Elena Casiraghi, Timothy Bergquist, Johanna J. Loomba, Tiffany J. Callahan, Bryan Laraway, Corneliu Antonescu, Ben Coleman, Michael Gargano, Kenneth J. Wilkins, Luca Cappelletti, Tommaso Fontana, Nariman Ammar, Blessy Antony, T.M. Murali, J. Harry Caufield, Guy Karlebach, Julie A. McMurry, Andrew Williams, Richard Moffitt, Jineta Banerjee, Anthony E. Solomonides, Hannah Davis, Kristin Kostka, Giorgio Valentini, David Sahner, Christopher G. Chute, Charisse Madlock-Brown, Melissa A. Haendel, Peter N. Robinson, Heidi Spratt, Shyam Visweswaran, Joseph Eugene Flack, IV, Yun Jae Yoo, Davera Gabriel, G. Caleb Alexander, Hemalkumar B. Mehta, Feifan Liu, Robert T. Miller, Rachel Wong, Elaine L. Hill, Lorna E. Thorpe, Jasmin Divers

Publikováno v: EBioMedicine, Vol 87, Iss , Pp 104413- (2023)

Summary: Background: Stratification of patients with post-acute sequelae of SARS-CoV-2 infection (PASC, or long COVID) would allow precision clinical management strategies. However, long COVID is incompletely understood and characterised by a wide ra

Externí odkaz: https://doaj.org/article/f4635ea98874437da59d335d9ba0de7a

Generalisable long COVID subtypes: Findings from the NIH N3C and RECOVER programmes

Autor: Justin T. Reese, Hannah Blau, Elena Casiraghi, Timothy Bergquist, Johanna J. Loomba, Tiffany J. Callahan, Bryan Laraway, Corneliu Antonescu, Ben Coleman, Michael Gargano, Kenneth J. Wilkins, Luca Cappelletti, Tommaso Fontana, Nariman Ammar, Blessy Antony, T.M. Murali, J. Harry Caufield, Guy Karlebach, Julie A. McMurry, Andrew Williams, Richard Moffitt, Jineta Banerjee, Anthony E. Solomonides, Hannah Davis, Kristin Kostka, Giorgio Valentini, David Sahner, Christopher G. Chute, Charisse Madlock-Brown, Melissa A. Haendel, Peter N. Robinson, Heidi Spratt, Shyam Visweswaran, Joseph Eugene Flack, Yun Jae Yoo, Davera Gabriel, G. Caleb Alexander, Hemalkumar B. Mehta, Feifan Liu, Robert T. Miller, Rachel Wong, Elaine L. Hill, Lorna E. Thorpe, Jasmin Divers

Publikováno v: EBioMedicine. 87

Stratification of patients with post-acute sequelae of SARS-CoV-2 infection (PASC, or long COVID) would allow precision clinical management strategies. However, long COVID is incompletely understood and characterised by a wide range of manifestations

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c6ace44d933867f392b11838ae4032b
https://pubmed.ncbi.nlm.nih.gov/36563487

Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

Autor: Thomas L. Holland, Adit A. Ginde, Roger Paredes, Thomas A. Murray, Nicole Engen, Greg Grandits, Andrew Vekstein, Noel Ivey, Ahmad Mourad, Uriel Sandkovsky, Robert L. Gottlieb, Mezgebe Berhe, Mamta K. Jain, Rubria Marines-Price, Barbine Tchamba Agbor Agbor, Lourdes Mateu, Sergio España-Cueto, Gemma Lladós, Eleftherios Mylonakis, Ralph Rogers, Fadi Shehadeh, Michael R. Filbin, Kathryn A. Hibbert, Kami Kim, Thanh Tran, Peter E. Morris, Evan P. Cassity, Barbara Trautner, Lavannya M. Pandit, Kirk U. Knowlton, Lindsay Leither, Michael A. Matthay, Angela J. Rogers, Wonder Drake, Beatrice Jones, Garyfallia Poulakou, Konstantinos N. Syrigos, Eduardo Fernández-Cruz, Marisa Di Natale, Eyad Almasri, Leire Balerdi-Sarasola, Sanjay R. Bhagani, Katherine L. Boyle, Jonathan D. Casey, Peter Chen, David J. Douin, D. Clark Files, Huldrych F. Günthard, R. Duncan Hite, Robert C. Hyzy, Akram Khan, Moses Kibirige, Robert Kidega, Ivan Kimuli, Francis Kiweewa, Jens-Ulrik Jensen, Bradley G. Leshnower, Joseph K. Lutaakome, Prasad Manian, Vidya Menon, Jose Luis Morales-Rull, D. Shane O'Mahony, J. Scott Overcash, Srikant Ramachandruni, Jay S. Steingrub, Hassan S. Taha, Michael Waters, Barnaby E. Young, Andrew N. Phillips, Daniel D. Murray, Tomas O. Jensen, Maria L. Padilla, David Sahner, Katy Shaw-Saliba, Robin L. Dewar, Marc Teitelbaum, Ven Natarajan, M. Tauseef Rehman, Sarah Pett, Fleur Hudson, Giota Touloumi, Samuel M. Brown, Wesley H. Self, Christina C. Chang, Adriana Sánchez, Amy C. Weintrob, Timothy Hatlen, Birgit Grund, Shweta Sharma, Cavan S. Reilly, Pedro Garbes, Mark T. Esser, Alison Templeton, Abdel G. Babiker, Victoria J. Davey, Annetine C. Gelijns, Elizabeth S. Higgs, Virginia Kan, Gail Matthews, B. Taylor Thompson, James D. Neaton, H. Clifford Lane, Jens D. Lundgren

Publikováno v: ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, Nielsen, H, Thisted, R K, Petersen, K T & Juhl, M R 2022, ' Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial ', The Lancet. Respiratory Medicine, vol. 10, no. 10, pp. 972-984 . https://doi.org/10.1016/S2213-2600(22)00215-6

BACKGROUND: Tixagevimab-cilgavimab is a neutralising monoclonal antibody combination hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to compare tixagevimab-cilgavimab versus placebo, in patients receiving remdesivir

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2d68ff5f7b45f40663551f557484e3a
https://pubmed.ncbi.nlm.nih.gov/36356600

Clinical Decision Support Using a Partially Instantiated Probabilistic Graphical Model Optimized through Quantum Annealing: Proof-of-Concept of a Computational Method Using a Clinical Data Set

Autor: David Sahner, Richard J. Williams

An approach is described to building a clinical decision support tool which leverages a partially instantiated graphical model optimized through quantum annealing. Potential advantages of such a strategy include the practical, and potentially real-ti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf9701f0a379d8c99bee68f92784baf7
https://doi.org/10.1101/2020.12.13.20248138

Artificial Intelligence: Emerging Applications in Biotechnology and Pharma

Autor: David Sahner, David C. Spellmeyer

Artificial intelligence (AI), specifically machine learning (ML) models that make biological or clinical predictions, may indeed be transformative within the realms of drug and biologic discovery and development. ML has already made inroads within th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::55622a5f67928fc7a52a03efa247d631
https://doi.org/10.1016/b978-0-12-815585-1.00028-0